Search research articles
Contact Us
Filters
Showing results (111-120 of 271) with videos related to
Page
of 28
Sort By:
Cancer
|
November 25, 2003
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi
Paolo G Gobbi, Chiara Broglia, Francesco Merli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
Massimo Federico, Monica Bellei, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2002
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up
Massimo Federico, Pier Luigi Zinzani, Antonio Frassoldati, et al.
Hemasphere
|
May 9, 2025
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up
Francesco d'Amore, Massimo Federico, Laurence de Leval, et al.
British Journal of Haematology
|
February 23, 2019
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)
Chiara Rusconi, Antonella Anastasia, Annalisa Chiarenza, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Adrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
Stefano Luminari, Alexander Fossa, Judith Trotman, et al.
Genes, Chromosomes & Cancer
|
May 23, 2006
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations
Simona Agata, Alessandra Viel, Lara Della Puppa, et al.
Leukemia & Lymphoma
|
May 3, 2008
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
Antonino Neri, Sandra Marmiroli, Pierfrancesco Tassone, et al.
Hematological Oncology
|
October 30, 2016
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, et al.
Page
of 28
Search research articles
Search
Showing results (111-120 of 271) with videos related to
Sort By:
Page
of 28
Cancer
|
November 25, 2003
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi
Paolo G Gobbi, Chiara Broglia, Francesco Merli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy
Massimo Federico, Monica Bellei, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2002
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up
Massimo Federico, Pier Luigi Zinzani, Antonio Frassoldati, et al.
Hemasphere
|
May 9, 2025
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up
Francesco d'Amore, Massimo Federico, Laurence de Leval, et al.
British Journal of Haematology
|
February 23, 2019
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)
Chiara Rusconi, Antonella Anastasia, Annalisa Chiarenza, et al.
Molecular Cancer Therapeutics
|
January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphoma
Adrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
Stefano Luminari, Alexander Fossa, Judith Trotman, et al.
Genes, Chromosomes & Cancer
|
May 23, 2006
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations
Simona Agata, Alessandra Viel, Lara Della Puppa, et al.
Leukemia & Lymphoma
|
May 3, 2008
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
Antonino Neri, Sandra Marmiroli, Pierfrancesco Tassone, et al.
Hematological Oncology
|
October 30, 2016
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients
Raffaella Marcheselli, Alessia Bari, Tamar Tadmor, et al.
Page
of 28